Can we predict chemotherapy response in patients with metastatic testicular cancer? Role of thrombocytosis as a novel marker

被引:1
作者
Gokce, Mehmet I. [1 ]
Mermerkaya, Murat [1 ]
Suer, Evren [1 ]
Afandiyev, Faraj [1 ]
Baltaci, Smer [1 ]
机构
[1] Ankara Univ, Sch Med, Dept Urol, Ankara, Turkey
关键词
Testicular neoplasms; Germ cell and embryonal neoplasms; Drug therapy; Thrombocytosis; GERM-CELL TUMORS; PREOPERATIVE THROMBOCYTOSIS; PROGNOSTIC-SIGNIFICANCE; CISPLATIN RESISTANCE; OVARIAN-CARCINOMA; COOPERATIVE GROUP; SURVIVAL; ETOPOSIDE; SEMINOMA;
D O I
10.23736/S0393-2249.16.02690-4
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND: Primary treatment of choice for advanced germ cell tumors is 3 to 4 cycles of combination bleomycin-etoposide-cisplatin (BEP) chemotherapy. Although most patients treated for advanced germ cell tumors (GCT) will be cured, approximately 30% will fail to achieve a durable complete response (CR). Thrombocytosis has been found to be related with significantly shorter survival in many cancers. However, its role in testicular cancer patients has not been studied previously. The objective of this study was to investigate the relationship between thrombocytosis and chemotherapy response in patients with metastatic testicular cancer. METHODS: Records of 113 patients with advanced stage testicular cancer were reviewed. Treatment outcomes were classified as complete clinical response (cCR), partial clinical response (pCR), complete pathological response (cPR) and treatment failure and the relationship with thrombocytosis was investigated. Logistic regression analysis was performed to identify factors associated with treatment failure. RESULTS: Totally 103 patients met the eligibility criteria. Thrombocytosis was detected in 26 (25.2%) patients. Treatment failure was observed in 14 (53.8%) and 28 (36.4%) of the patients in the thrombocytosis and non-thrombocytosis groups respectively (P=0.037). Thrombocytosis and IGCCCG high-risk group are found as independent prognostic factors for treatment failure in multivariate analysis. CONCLUSIONS: Thrombocytosis is seen in 25% of patients with testicular GCT and it is found to be associated with poorer chemotherapy response in metastatic patients. It can be used to predict the response to chemotherapy.
引用
收藏
页码:342 / 348
页数:7
相关论文
共 28 条
[21]  
Mead G M, 1997, Clin Oncol (R Coll Radiol), V9, P207, DOI 10.1016/S0936-6555(97)80001-5
[22]  
Monreal M, 1998, THROMB HAEMOSTASIS, V79, P916
[23]   Platelet number and interleukin-6 correlate with VEGF but not with bFGF serum levels of advanced cancer patients [J].
Salgado, R ;
Vermeulen, PB ;
Benoy, I ;
Weytjens, R ;
Huget, P ;
Van Marck, E ;
Dirix, LY .
BRITISH JOURNAL OF CANCER, 1999, 80 (5-6) :892-897
[24]   Pretreatment Thrombocytosis as a Prognostic Factor in Metastatic Breast Cancer [J].
Stravodimou, Athina ;
Voutsadakis, Ioannis A. .
INTERNATIONAL JOURNAL OF BREAST CANCER, 2013, 2013
[25]   Thrombocytosis as a prognostic factor for survival in patients with metastatic renal cell carcinoma [J].
Suppiah, Revathi ;
Shaheen, Philip E. ;
Elson, Paul ;
Misbah, Seema A. ;
Wood, Laura ;
Motzer, Robert J. ;
Negrier, Slyvie ;
Andresen, Steven W. ;
Bukowski, Ronald M. .
CANCER, 2006, 107 (08) :1793-1800
[26]   Poor prognosis associated with thrombocytosis in patients with renal cell carcinoma [J].
Symbas, NP ;
Townsend, MF ;
El-Galley, R ;
Keane, TE ;
Graham, SD ;
Petros, JA .
BJU INTERNATIONAL, 2000, 86 (03) :203-207
[27]   Global DNA methylation in fetal human germ cells and germ cell tumours: association with differentiation and cisplatin resistance [J].
Wermann, Hendrik ;
Stoop, Hans ;
Gills, Ad J. M. ;
Honecker, Friedemann ;
van Gurp, Ruud J. H. L. M. ;
Ammerpohl, Ole ;
Richter, Julia ;
Oosterhuis, J. Wolter ;
Bokemeyer, Carsten ;
Looijenga, Leendert H. J. .
JOURNAL OF PATHOLOGY, 2010, 221 (04) :433-442
[28]   Distinctive epigenetic phenotype of cancer testis antigen genes among seminomatous and nonseminomatous testicular germ-cell tumors [J].
Zhang, C ;
Kawakami, T ;
Okada, Y ;
Okamoto, K .
GENES CHROMOSOMES & CANCER, 2005, 43 (01) :104-112